Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01948141 · ClinicalTrials.gov registry record · Phase 2
Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens
A Phase 2 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT01948141 is a Phase 2 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 6 participants.
The verdict
NCT01948141, a Phase 2 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This phase II trial studies how well nintedanib works in treating patients with advanced non-small cell lung cancer who have failed up to two previous chemotherapy regimens. Nintedanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG nintedanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2014-01-30 |
| Est. Completion | 2016-08-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01948141
The ClinicalTrials.gov registry entry for NCT01948141 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which nintedanib is the first listed.
NCT01948141 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01948141 about?
NCT01948141 is a clinical study titled "Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens". This phase II trial studies how well nintedanib works in treating patients with advanced non-small cell lung cancer who have failed up to two previous chemotherapy regimens. Nintedanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
What is the current status of trial NCT01948141?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2014-01-30. Estimated completion is 2016-08-16.
What interventions are being tested in trial NCT01948141?
The interventions under investigation include: nintedanib (DRUG).
Who is sponsoring clinical trial NCT01948141?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.